DOE OSTI · 1671108
A reverse 230 U/ 226 Th radionuclide generator for targeted alpha therapy applications
Abstract
Thorium-226 (half-life 30.6 m) is a radionuclide of interest for use in targeted alpha therapy applications. Additionally, due to its short half-life, 226 Th must be provided through a radionuclide generator system from its parent 230 U (20.8 d). Furthermore, as the half-life of 226 Th is very short, it should be provided in a form that is directly amenable to use in biomedical applications.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Mastren, Tara, Akin, Andrew, Copping, Roy, Brugh, Mark, Wilbur, D. Scott, Birnbaum, Eva R., Nortier, Francois M., John, Kevin D., Fassbender, Michael E.. 2020-09-30. A reverse 230 U/ 226 Th radionuclide generator for targeted alpha therapy applications. https://doi.org/10.1016/j.nucmedbio.2020.09.006
Cite the original work for its findings. Save a collection to share your selection of sources.